The Impact of FLT3 Inhibitors for the Treatment of AML

Video

Meir Wetzler, MD, from Roswell Park Cancer Institute, discusses the potential impact of FLT3 inhibitors for the treatment of patients with acute myeloid leukemia.

Clinical Pearls

Meir Wetzler, MD, chief, Leukemia Section, Department of Medicine, Professor of Medicine, Department of Medicine, Roswell Park Cancer Institute, discusses the potential impact of FLT3 inhibitors for the treatment of patients with acute myeloid leukemia.

  • In CML, initially only imatinib was available in the frontline, but now nilotinib and dasatinib are approved.
  • FLT3 inhibitors did not show significant efficacy in the relapsed/refractory setting of AML, so they were evaluated in the frontline.
Related Videos
Gary J. Schiller, MD, an expert on MDS
Gary J. Schiller, MD, an expert on MDS
Jamie Koprivnikar, MD, and Hana Safah, MD, experts on MDS
Related Content